Skandinaviska Enskilda Banken (SEB)’s BioCryst Pharmaceuticals BCRX Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-114,063	Closed	-$1.02M	–	801
2025 Q2	$1.02M	Hold	114,063	–	–	﹤0.01%	646
2025 Q1	$855K	Hold	114,063	–	–	﹤0.01%	655
2024 Q4	$859K	Hold	114,063	–	–	﹤0.01%	670
2024 Q3	$867K	Hold	114,063	–	–	﹤0.01%	683
2024 Q2	$705K	Hold	114,063	–	–	﹤0.01%	663
2024 Q1	$579K	Sell	114,063 -76,478	-40%	-$430K	﹤0.01%	699
2023 Q4	$1.14M	Hold	190,541	–	–	0.01%	680
2023 Q3	$1.35M	Hold	190,541	–	–	0.01%	630
2023 Q2	$1.34M	Buy	190,541 +96,101	+102%	+$771K	0.01%	647
2023 Q1	$788K	Sell	94,440 -4,646	-5%	-$44.7K	0.01%	724
2022 Q4	$1.14M	Sell	99,086 -5,743	-5%	-$71.6K	0.01%	655
2022 Q3	$1.32M	Hold	104,829	–	–	0.01%	619
2022 Q2	$1.11M	Hold	104,829	–	–	0.01%	692
2022 Q1	$1.71M	Hold	104,829	–	–	0.01%	654
2021 Q4	$1.45M	Hold	104,829	–	–	0.01%	719
2021 Q3	$1.51M	Buy	+104,829	New	+$1.65M	0.01%	716

Other funds holding BCRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s BCRX Position: Q3 2025 in Review

Skandinaviska Enskilda Banken (SEB) sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2025, closing a stake of 114,063 shares — an estimated $1.02M sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in BCRX in Q3 2021 and held it in 16 quarters. The position peaked at $1.71M in Q1 2022. 286 funds tracked by Wall St. Rank hold BCRX as of Q3 2025.

Skandinaviska Enskilda Banken (SEB) reported no remaining BioCryst Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Skandinaviska Enskilda Banken (SEB) sold 114,063 BioCryst Pharmaceuticals shares in Q3 2025, an estimated $1.02M.
Skandinaviska Enskilda Banken (SEB) first reported a position in BioCryst Pharmaceuticals in Q3 2021 and held it in 16 quarters.
Skandinaviska Enskilda Banken (SEB)'s BioCryst Pharmaceuticals position peaked at $1.71M in Q1 2022.
286 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2025.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q3 2025, filed 7 Nov 2025.